Sangamo FY2024 net loss $97.9M; FDA clears ST-503 IND; Fabry BLA path to Accelerated Approval

SANGAMO THERAPEUTICS, INC

FY2024 net loss $97.9M ($0.49/share) vs $257.8M ($1.48) in 2023; revenue $57.8M vs $176.2M.
Cash $41.9M at Dec 31, 2024; with $10.1M ATM proceeds and $5M Pfizer payment, funds operations into mid-Q2 2025.
FDA cleared IND for ST-503 (chronic neuropathic pain); patient enrollment expected mid-2025; preliminary efficacy data Q4 2026.
FDA agreed to Accelerated Approval for isaralgagene civaparvovec in Fabry using Phase 1/2 data; BLA submission H2 2025.
License agreements with Genentech (Aug 2024) and Astellas (Dec 2024) for STAC-BBB capsid; $20M upfront from Astellas.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.